Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
SMSummit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT)

NASDAQ Global Market · Currency in USD
$15.47 ▼ -0.08 (-0.51%)
At close: Oct 23, 4:00 PM ET. Market closed.
$15.51 ▲ +0.04 (+0.27%)
After hours: Oct 23, 7:59 PM ET

Summary

Previous Close
$15.55
Open
$15.46
Day's Range
$15.08 – $15.55
52 Week Range
$12.07 – $29.23
Volume
3,204,748
Avg. Volume
5,628,797
Market Cap
$12.34B
Beta (5Y Monthly)
-1.24
PE Ratio (TTM)
--
EPS (TTM)
-$1.10
Earnings Date
Oct 26, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$29.33

Profile: Summit Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
265
CEO
Robert W. Duggan
Website
smmttx.com

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI.

Earnings

Next report: Mon, Oct 26, 2026
EPS estimate -$0.28 · Revenue est. $71.43K
DateEst.Actual
Jul 23, 2026-$0.27-$0.28Miss
Apr 30, 2026-$0.33-$0.24Beat
Feb 23, 2026-$0.10-$0.29Miss
Oct 20, 2025-$0.18-$0.31Miss
Aug 11, 2025-$0.09-$0.76Miss
May 1, 2025-$0.09-$0.09Beat

Analyst view

Consensus price target
$29.33 ▲ +89.6%
Range $16.00 – $41.00
Rating: Buy
Buy 65% · Hold 35% · Sell 0%

Get free alerts on SMMT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.